Axsome Therapeutics (AXSM) Announces Collaboration with Duke University Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation
Tweet Send to a Friend
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE